Simulations Plus Inc. on Wednesday announced the release of the latest version of its main software product GastroPlus.

The Lancaster company provides modeling and simulation software for pharmaceutical and chemical research. Its newest launch, GastroPlus Version 9.5, has added features that John DiBella, Simulations Plus’ vice president of marketing and sales, said should “drive further adoption” of the platform.

“GastroPlus has served as the industry’s workhorse software for oral drug development activities for many years, and we have invested heavily to extend the utility of the program to serve other research functions,” DiBella said in a statement. “We have also been fortunate to enter into several funded collaborations with industry and secure multiple grant awards from the U.S. FDA, which has resulted in the ongoing development of the Additional Dosage Routes Module that is now being licensed to numerous organizations.”

Some of the software’s new features include new models for antibody-drug conjugates and injection formulations, upgraded workflows for trial simulations and improved reporting capabilities for regulatory submissions.

Simulations Plus (SLP) shares closed down 10 cents, or less than a percent, to $10.95 on the Nasdaq.